Erasca Advances RAS-Targeted Pipeline with Strong Q1 2026 Data and Strategic Collaborations
Event summary
- Erasca reported robust monotherapy efficacy and favorable safety results for ERAS-0015 in KRAS G12X NSCLC and PDAC during dose escalation.
- The company expects ERAS-0015 monotherapy expansion and combination dose escalation data in H1 2027, and ERAS-4001 Phase 1 preliminary monotherapy data in H2 2026.
- Erasca's cash position stood at $409 million as of March 31, 2026, expected to fund operations into H2 2028.
- Erasca entered into clinical trial collaboration agreements with Merck and Tango Therapeutics for ERAS-0015 combinations.
The big picture
Erasca's Q1 2026 updates highlight its aggressive push in the RAS-targeted oncology space, with promising early data for ERAS-0015 and strategic collaborations aimed at accelerating development. The company's strong cash position provides a solid runway, but the success of its pipeline will depend on the outcomes of upcoming clinical trials and the ability to secure additional partnerships. The broader industry is watching closely, as RAS-targeted therapies represent a significant unmet need in precision oncology.
What we're watching
- Clinical Progress
- Whether ERAS-0015 can maintain its best-in-class potential through monotherapy expansion and combination trials.
- Financial Runway
- The pace at which Erasca's $409 million cash position will be depleted, given its current R&D and operational expenses.
- Strategic Collaborations
- How the partnerships with Merck and Tango Therapeutics will impact the development and commercialization of ERAS-0015.
Related topics